

## Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective

**Authors:** Cosphiadi Irawan<sup>1\*</sup>, Erna Kristin<sup>2</sup>, Susanna Hilda Hutajulu<sup>3</sup>, Yussy Afriani Dewi<sup>4</sup>, Gregorius Ben Prajogi<sup>5</sup>, Lucia Rizka Andalucia<sup>6</sup>, Donni Hendrawan<sup>7</sup>, Sudi Indrajaya<sup>2</sup>, Royasia Ramadani<sup>8</sup>, See-Hwee Yeo<sup>8</sup>, Shikha Dhawan<sup>9</sup>, Junice Ng<sup>10</sup>

\*Presenting author

**Affiliations:** <sup>1</sup>Internal Medicine, Dr. Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; <sup>2</sup>Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Yogyakarta, Indonesia; <sup>3</sup>Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr Sardjito General Hospital, Yogyakarta, Indonesia; <sup>4</sup>Department of Otorhinolaryngology–Head and Neck Surgery, Faculty of Medicine Padjadjaran University, Hasan Sadikin General Hospital, Bandung, Indonesia; <sup>5</sup>Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia; <sup>6</sup>Department of Pharmaceutical and Medical Devices, Ministry of Health, Jakarta, Indonesia; <sup>7</sup>Research, Innovation and Development Department, BPJS Kesehatan, Jakarta, Indonesia; <sup>8</sup>Real World Solutions, IQVIA Solutions Asia, Singapore, Singapore; <sup>9</sup>BeiGene, Inc., Medical Affairs Southeast Asia, Singapore; <sup>10</sup>BeiGene, Inc., Global HEOR, Singapore

### ABSTRACT

**Background:** Nasopharyngeal carcinoma (NPC) is a common and deadly cancer in Indonesia. The objective of this study is to estimate the direct medical hospital costs of NPC using the national health insurance (*Jaminan Kesehatan Nasional [JKN]*) database in Indonesia.

**Methods:** The annual costs were estimated using a nationally representative sample of 1% of the JKN population, comprising 2.1 (2019) to 2.4 million (2022) JKN members, from 2019 to 2022. Patients newly diagnosed with NPC, who had at least two NPC-related visits and no prior cancer diagnosis in the year before, were included. Annual costs were calculated over one year (365 days) from the first visit associated with NPC. Costs captured under case-based groups (CBGs) comprised hospitalization and specialist outpatient visits. Non-CBGs costs included radiotherapy, diagnostic procedures, and other costs such as prostheses. Chemotherapy costs were not available for analysis. Costs in Indonesian Rupiah (IDR) were inflated using the Consumer Price Index in 2022 and converted to United States dollars (USD) (1 USD = IDR 15,731).

**Results:** Of the 590 NPC patients with records in JKN, 262 patients met the inclusion criteria. Around 29% of these patients did not receive any NPC-related treatment one year after diagnosis. The annual mean cost was USD \$4,644 per patient. CBGs accounted for 92% of the total mean cost, with inpatient and outpatient CBGs costing USD \$2,014 and USD \$2,278 per patient, respectively. Non-CBGs cost per patient was USD \$353. The total direct medical hospital cost for all NPC patients in the JKN population was extrapolated to be USD \$40.5 million per year. This comprised 14% of the JKN cancer expenditure.

**Conclusions:** NPC imposes a significant economic burden on Indonesia's health system. To contain health expenditures, specific policies are needed to improve cancer prevention and early diagnosis, as well as to efficiently allocate healthcare resources.